-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE MINNESOTA VETERINARY MEDICAL ASSOCIATION ANNUAL MEETING IN MINNEAPOLIS, MINNESOTA
PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE MINNESOTA VETERINARY MEDICAL ASSOCIATION ANNUAL MEETING IN MINNEAPOLIS, MINNESOTA
MINNEAPOLIS, Jan. 30, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals today announced it will be exhibiting at the 2023 Minnesota Veterinary Medical Association Annual Meeting from February 2nd to February 4th, 2023 at the Hyatt Regency in Minneapolis, Minnesota.
"We are incredibly excited to showcase our innovative product for the management of lameness, Spryng™ with OsteoCushion™ Technology to the veterinary professionals in our own home state," said John Lai, Chief Executive Officer, at PetVivo Holdings, Inc. "We invite all MVMA annual meeting attendees to stop by our PetVivo booth #226 to learn more."
Spryng is an injectable veterinary medical device comprised of millions of micronized extracellular matrix particles, which are derived from natural components, including collagen and elastin. OsteoCushion Technology provides both reinforcing natural joint support to augment and/or reinforce missing and damaged cartilage, as well as delivers natural scaffolding to help address tissue defects. These attributes offer a great solution to manage lameness and joint afflictions, such as osteoarthritis, for companion animals in a simple in-clinic administration.
For more information about PetVivo Holdings, Inc. please contact info1@petvivo.com or visit
Conference Details:
2023 Minnesota Veterinary Association Annual Meeting
Dates:
Thursday, February 2, 2023 10:50am – 5:30pm
Friday February 3, 2023 7:45am – 7:00pm
Saturday February 4, 2023 7:30am – 11:00am
Location: Hyatt Regency, Minneapolis, Minnesota
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products at various stages of development and/or commercialization for the treatment of animals and people. A portfolio of nineteen patents protects the Company's biomaterials, products, production processes and methods of use. The Company's lead product SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale.
For more information about PetVivo Holdings, Inc. and our revolutionary product, Spryng with OsteoCushion Technology, please contact info1@petvivo.com or visit
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking commercial Statements:
The foregoing material may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's proposed development and commercial timelines, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the potential listing of the Company's common stock on Nasdaq, are based on information currently available the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company's business are described in detail in the Company's Annual Report on Form 10-K for the year ended March 31, 2022 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
MINNEAPOLIS, Jan. 30, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals today announced it will be exhibiting at the 2023 Minnesota Veterinary Medical Association Annual Meeting from February 2nd to February 4th, 2023 at the Hyatt Regency in Minneapolis, Minnesota.
明尼阿波利斯,2023年1月30日(環球網)--PetVivo控股公司(納斯達克代碼:PETV&PETVW)今天宣佈,它將參加2023年2月2日至2月4日在明尼蘇達州凱悦酒店舉行的2023年明尼蘇達州獸醫協會年會。
"We are incredibly excited to showcase our innovative product for the management of lameness, Spryng™ with OsteoCushion™ Technology to the veterinary professionals in our own home state," said John Lai, Chief Executive Officer, at PetVivo Holdings, Inc. "We invite all MVMA annual meeting attendees to stop by our PetVivo booth #226 to learn more."
我們非常興奮地展示了我們用於治療跛行的創新產品Spryng™與OsteoCushion合作™PetVivo控股公司的首席執行官John Lai説:“我們邀請所有參加MVMA年會的人到我們的PetVivo#226號展臺瞭解更多信息。”
Spryng is an injectable veterinary medical device comprised of millions of micronized extracellular matrix particles, which are derived from natural components, including collagen and elastin. OsteoCushion Technology provides both reinforcing natural joint support to augment and/or reinforce missing and damaged cartilage, as well as delivers natural scaffolding to help address tissue defects. These attributes offer a great solution to manage lameness and joint afflictions, such as osteoarthritis, for companion animals in a simple in-clinic administration.
Spryng是一種可注射的獸醫設備,由數百萬微粉化的細胞外基質顆粒組成,這些顆粒來自天然成分,包括膠原和彈性蛋白。OsteoCushion技術既提供增強的自然關節支撐,以增強和/或增強丟失和/或損壞的軟骨,也提供自然支架,以幫助解決組織缺陷。這些屬性提供了一個很好的解決方案來管理跛行和關節痛苦,如骨關節炎,在一個簡單的診所給藥的同伴動物。
For more information about PetVivo Holdings, Inc. please contact info1@petvivo.com or visit
欲獲知更多有關PetVivo控股公司的信息,請聯繫info1@petvivo.com或訪問
Conference Details:
會議詳細信息:
2023 Minnesota Veterinary Association Annual Meeting
2023年明尼蘇達州獸醫協會年會
Dates:
日期:
Thursday, February 2, 2023 10:50am – 5:30pm
2023年2月2日星期四上午10:50-下午5:30
Friday February 3, 2023 7:45am – 7:00pm
2023年2月3日星期五上午7:45-晚上7:00
Saturday February 4, 2023 7:30am – 11:00am
2023年2月4日星期六上午7:30-11:00
Location: Hyatt Regency, Minneapolis, Minnesota
地點:明尼蘇達州明尼阿波利斯凱悦酒店
About PetVivo Holdings, Inc.
關於PetVivo控股公司
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo控股公司(納斯達克代碼:PETV&PETVW)是一家新興的生物醫療設備公司,目前專注於為同伴動物製造、商業化和許可創新的醫療設備和治療藥物。該公司的戰略是利用人類療法以一種既省錢又省時的方式治療同伴動物。這一戰略的一個關鍵組成部分是加快獸醫醫療設備收入的時間表,這些設備進入市場的時間比監管更嚴格的藥品和生物製品早得多。
PetVivo has a robust pipeline of products at various stages of development and/or commercialization for the treatment of animals and people. A portfolio of nineteen patents protects the Company's biomaterials, products, production processes and methods of use. The Company's lead product SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale.
PetVivo在動物和人類治療的不同開發和/或商業化階段擁有強大的產品流水線。共有19項專利保護該公司的生物材料、產品、生產工藝和使用方法。該公司的主導產品Spryng™與OsteoCushion合作™Technology是一種由獸醫管理的關節內注射,用於治療狗和馬的跛行和其他關節相關疾病,包括骨關節炎,目前可用於商業銷售。
For more information about PetVivo Holdings, Inc. and our revolutionary product, Spryng with OsteoCushion Technology, please contact info1@petvivo.com or visit
欲瞭解有關PetVivo控股公司和我們的革命性產品Spryng with OsteoCushion Technology的更多信息,請聯繫info1@petvivo.com或訪問
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
聯繫方式:
首席執行官黎智英
PetVivo控股公司
電子郵件:info1@petvivo.com
(952) 405-6216
Forward-Looking commercial Statements:
前瞻性商業聲明:
The foregoing material may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's proposed development and commercial timelines, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the potential listing of the Company's common stock on Nasdaq, are based on information currently available the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company's business are described in detail in the Company's Annual Report on Form 10-K for the year ended March 31, 2022 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
上述材料可能包含1933年《證券法》第27A節和1934年《證券交易法》第21E節(均經修訂)所指的“前瞻性陳述”。前瞻性陳述包括所有不完全與歷史或當前事實有關的陳述,包括但不限於公司建議的開發和商業時間表,可以通過使用“可能”、“將”、“預期”、“項目”、“估計”、“預期”、“計劃”、“相信”、“潛在”、“應該”、“繼續”或這些詞語的否定版本或其他類似詞語來識別。前瞻性陳述不是對未來行動或業績的保證。這些前瞻性陳述,包括公司普通股可能在納斯達克上市的可能性,是基於公司及其當前計劃或預期的現有信息,會受到一些不確定性和風險的影響,這些不確定性和風險可能會對現有計劃產生重大影響。與公司業務有關的風險在公司截至2022年3月31日的10-K表格年度報告以及提交給證券交易委員會的其他定期報告和當前報告中有詳細描述。無論是由於新信息、未來事件或其他原因,公司沒有義務更新或改變其前瞻性陳述,並明確表示不承擔任何此類義務。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧